CLINICAL TRIAL TO EVALUATE BLADDER INSTILLATION OF NEOADJUVANT CHEMOTHERAPY TO TRANSURETHRAL RESECTION OF THE BLADDER FOR THE PREVENTION OF RECURRENCE OF NON-MUSCLE INVASIVE UROTHELIAL CARCINOMA

Prior treatment

• Patients with severe urethral stricture or inability to catheterize the bladder for any other reason prior to TURBT.

Other illness

• Patients with a history of allergy to Mitomycin C, Epirubicin, Adriamycin, Cisplatin, Gemcitabine, Docetaxel.

Other

• Tumors of solid or muscle invasive appearance on cystoscopy and/or preoperative imaging tests.
• Pregnant patients.
• Patients in whom it is foreseen that follow-up is not going to be possible for any reason.
• Patients who for any reason should not be included in the study according to the evaluation of the research team.
• Patients will be excluded from the clinical trial if, after TURBT, their pathological anatomy report shows a diagnosis other than papillary type IMIBC (CIS only, benign lesions, muscle invasive bladder carcinoma, etc.).
• Patients with tumors ≥ 3 cm will not be included.

• Patients of both sexes aged ≥ 18 years.
• Patients with clinical and/or imaging evidence of CVNMI with indication for TURBT.
• Patients with a history of stage CVNMI: Ta/T1, G1-G3, without concomitant CIS (Carcinoma in situ), provided they have a disease-free period of at least 6 months.
• Karnofsky scale score > 70%.
• Patients who agree to participate in the study by signing the informed consent.
• Patients with tumors <3 cm.